Equities research analysts expect Odonate Therapeutics Inc (NASDAQ:ODT) to announce earnings of ($0.86) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Odonate Therapeutics’ earnings. The business is expected to announce its next quarterly earnings report on Wednesday, May 9th.
According to Zacks, analysts expect that Odonate Therapeutics will report full-year earnings of ($4.30) per share for the current year. For the next financial year, analysts forecast that the firm will post earnings of ($4.46) per share. Zacks Investment Research’s EPS averages are a mean average based on a survey of research analysts that cover Odonate Therapeutics.
Odonate Therapeutics (NASDAQ:ODT) last issued its quarterly earnings results on Wednesday, February 14th. The company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.14).
ODT has been the subject of a number of research reports. Jefferies Group initiated coverage on shares of Odonate Therapeutics in a report on Tuesday, January 2nd. They issued a “buy” rating and a $40.00 price target for the company. Cowen initiated coverage on shares of Odonate Therapeutics in a report on Tuesday, January 2nd. They issued an “outperform” rating for the company. Goldman Sachs Group initiated coverage on shares of Odonate Therapeutics in a report on Tuesday, January 2nd. They issued a “neutral” rating and a $27.00 price target for the company. Finally, Zacks Investment Research downgraded shares of Odonate Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday.
Shares of Odonate Therapeutics (NASDAQ ODT) traded up $0.35 during trading on Wednesday, reaching $30.45. 42,110 shares of the company’s stock were exchanged, compared to its average volume of 47,008. Odonate Therapeutics has a 12-month low of $15.15 and a 12-month high of $32.00.
In other Odonate Therapeutics news, CEO Kevin C. Tang acquired 128,255 shares of Odonate Therapeutics stock in a transaction dated Friday, February 16th. The stock was bought at an average cost of $22.47 per share, with a total value of $2,881,889.85. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Kevin C. Tang acquired 39,083 shares of Odonate Therapeutics stock in a transaction dated Thursday, February 22nd. The shares were acquired at an average cost of $27.17 per share, with a total value of $1,061,885.11. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 1,502,666 shares of company stock valued at $36,136,851.
Large investors have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. bought a new position in shares of Odonate Therapeutics during the 4th quarter worth about $660,000. RTW Investments LP bought a new position in shares of Odonate Therapeutics during the 4th quarter worth about $725,000. Chartwell Investment Partners LLC bought a new position in shares of Odonate Therapeutics during the 4th quarter worth about $755,000. Millennium Management LLC bought a new position in shares of Odonate Therapeutics during the 4th quarter worth about $2,277,000. Finally, Victory Capital Management Inc. bought a new position in shares of Odonate Therapeutics during the 4th quarter worth about $2,611,000. 77.76% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://www.thelincolnianonline.com/2018/03/14/odonate-therapeutics-inc-odt-expected-to-post-earnings-of-0-86-per-share.html.
About Odonate Therapeutics
Odonate Therapeutics, Inc, formerly Odonate Therapeutics, LLC, is a pharmaceutical company. The Company is engaged in the development of therapeutics to improve and extend the lives of patients with cancer. It is focused on the development of tesetaxel, a novel chemotherapy agent. It has completed Phase-II studies in patients with metastatic breast cancer (MBC).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.